MX2023003685A - Anticuerpos anti-cd94 y metodos de uso de los mismos. - Google Patents
Anticuerpos anti-cd94 y metodos de uso de los mismos.Info
- Publication number
- MX2023003685A MX2023003685A MX2023003685A MX2023003685A MX2023003685A MX 2023003685 A MX2023003685 A MX 2023003685A MX 2023003685 A MX2023003685 A MX 2023003685A MX 2023003685 A MX2023003685 A MX 2023003685A MX 2023003685 A MX2023003685 A MX 2023003685A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- human
- methods
- bind
- promote
- Prior art date
Links
- 101100127356 Homo sapiens KLRD1 gene Proteins 0.000 abstract 3
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 abstract 3
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 abstract 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- -1 host cells Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a anticuerpos que se unen a CD94 de humano, así como métodos, usos, polinucleótidos, vectores, células huésped, y composiciones farmacéuticas relacionadas con los mismos. En algunas modalidades, los anticuerpos son anticuerpos humanos o humanizados que se unen a CD94 de humano y no bloquean la unión entre CD94 y HLA-E. En algunas modalidades, los anticuerpos reaccionan de forma cruzada con CD94 de cynomolgus. En algunas modalidades, los anticuerpos no promueven la internalización de CD94 expresado en la superficie en la medida de los anticuerpos existentes. En algunas modalidades, los anticuerpos promueven células dirigidas a ADCC que expresan CD94 de humano, por ejemplo, en la superficie celular.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063085932P | 2020-09-30 | 2020-09-30 | |
US202063088926P | 2020-10-07 | 2020-10-07 | |
PCT/US2021/052668 WO2022072508A1 (en) | 2020-09-30 | 2021-09-29 | Anti-cd94 antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003685A true MX2023003685A (es) | 2023-06-02 |
Family
ID=80950868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003685A MX2023003685A (es) | 2020-09-30 | 2021-09-29 | Anticuerpos anti-cd94 y metodos de uso de los mismos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US11795228B2 (es) |
EP (1) | EP4221752A1 (es) |
JP (1) | JP2023543835A (es) |
KR (1) | KR20230104611A (es) |
AU (1) | AU2021352981A1 (es) |
CA (1) | CA3197662A1 (es) |
IL (1) | IL301764A (es) |
MX (1) | MX2023003685A (es) |
WO (1) | WO2022072508A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023183926A1 (en) * | 2022-03-25 | 2023-09-28 | Dren Bio, Inc. | Anti-cd94 antibodies and methods of use thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE149841T1 (de) | 1990-01-26 | 1997-03-15 | Immunomedics Inc | Impfstoffe gegen krebs und infektionskrankheiten |
GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
DK2270149T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE. |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
WO2003085102A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
KR20070055625A (ko) | 2002-12-16 | 2007-05-30 | 제넨테크, 인크. | 이뮤노글로불린 변이체 및 이들의 용도 |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
US20070178106A1 (en) | 2004-04-30 | 2007-08-02 | Innate Pharma, S.A. | Compositions and methods for enhancing nk cell activity |
RU2481356C2 (ru) | 2004-12-28 | 2013-05-10 | Иннейт Фарма | Моноклональные антитела против nkg2a |
AU2006301163B2 (en) * | 2005-10-14 | 2012-02-23 | Innate Pharma | Compositions and methods for treating proliferative disorders |
AU2007276294B2 (en) | 2006-06-30 | 2012-11-29 | Novo Nordisk A/S | Anti-NKG2A antibodies and uses thereof |
BRPI0908508A2 (pt) * | 2008-01-24 | 2016-03-22 | Novo Nordisk As | anticorpo monoclonal nkg2a anti-humano humanizado |
CN103635487B (zh) | 2011-06-17 | 2016-10-12 | 诺沃—诺迪斯克有限公司 | 选择性消除侵蚀性细胞 |
HUE044704T2 (hu) | 2014-09-16 | 2019-11-28 | Innate Pharma | Kezelési rendek anti-NKG2A ellenanyagok alkalmazásával |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
US20220185895A1 (en) | 2019-03-29 | 2022-06-16 | Dren Bio, Inc. | Methods of reducing large granular lymphocyte and natural killer cell levels |
-
2021
- 2021-09-29 KR KR1020237014582A patent/KR20230104611A/ko unknown
- 2021-09-29 MX MX2023003685A patent/MX2023003685A/es unknown
- 2021-09-29 IL IL301764A patent/IL301764A/en unknown
- 2021-09-29 AU AU2021352981A patent/AU2021352981A1/en active Pending
- 2021-09-29 WO PCT/US2021/052668 patent/WO2022072508A1/en active Application Filing
- 2021-09-29 JP JP2023519659A patent/JP2023543835A/ja active Pending
- 2021-09-29 EP EP21876402.5A patent/EP4221752A1/en active Pending
- 2021-09-29 US US17/489,385 patent/US11795228B2/en active Active
- 2021-09-29 CA CA3197662A patent/CA3197662A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022072508A1 (en) | 2022-04-07 |
US11795228B2 (en) | 2023-10-24 |
JP2023543835A (ja) | 2023-10-18 |
IL301764A (en) | 2023-05-01 |
KR20230104611A (ko) | 2023-07-10 |
EP4221752A1 (en) | 2023-08-09 |
AU2021352981A1 (en) | 2023-06-08 |
CA3197662A1 (en) | 2022-04-07 |
US20220127365A1 (en) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500438A1 (en) | Anti-gcc antibody molecules and related compositions and methods | |
MX2021013336A (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
WO2016150899A3 (en) | Anti-ceacam6 antibodies and uses thereof | |
NZ708182A (en) | Bispecific t cell activating antigen binding molecules | |
MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
MX2020009463A (es) | Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor. | |
WO2016164731A3 (en) | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell | |
JOP20200259A1 (ar) | مستقبلات خيمرية لـ dll3 وطرق استخدامها | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
MX2020000342A (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos. | |
NZ731633A (en) | Antibodies against cd73 and uses thereof | |
PH12014502437A1 (en) | Anti-egfr antibodies and uses threof | |
MX2022007288A (es) | Agentes de union a ilt3 y metodos de uso de los mismos. | |
MX361929B (es) | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. | |
MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
IN2012DN05101A (es) | ||
WO2015069922A3 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use | |
MX2011009220A (es) | Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1. | |
MX2022016544A (es) | Agentes de union a lair-1 y metodos para su uso. | |
WO2021048564A3 (en) | Antigen-binding domain | |
CR20210091A (es) | Receptores químericos de steap1 y métodos de uso de los mismos antecedentes de la invención | |
WO2020065330A3 (en) | Chimeric antigen receptor | |
MX2023003685A (es) | Anticuerpos anti-cd94 y metodos de uso de los mismos. |